Biomx Inc
PHGE0.421USD
+0.024+6.15%
Market hours （ET）Quotes delayed by 15 min
10.51MMarket Cap
LossP/E TTM
More Details of Biomx Inc Company
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Company Info
Ticker SymbolPHGE
Company nameBiomx Inc
IPO dateDec 18, 2018
CEOMr. Jonathan Eitan Solomon
Number of employees52
Security typeOrdinary Share
Fiscal year-endDec 18
Address22 Einstein St.
CityNESS-ZIONA
Stock exchangeNYSE American Consolidated
CountryIsrael
Postal code7414003
Phone972723942377
Websitehttps://www.biomx.com/
Ticker SymbolPHGE
IPO dateDec 18, 2018
CEOMr. Jonathan Eitan Solomon
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
179.80K
+238.89%
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
68.92K
+18278.67%
Mr. Assaf Oron
Mr. Assaf Oron
Chief Business Officer
Chief Business Officer
25.80K
--
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Michael Dambach
Mr. Michael Dambach
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Director
Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Director
Director
--
--
Ms. Anat Primovich
Ms. Anat Primovich
Corporate Project Manager
Corporate Project Manager
--
--
Mr. Jason Marks
Mr. Jason Marks
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
179.80K
+238.89%
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
68.92K
+18278.67%
Mr. Assaf Oron
Mr. Assaf Oron
Chief Business Officer
Chief Business Officer
25.80K
--
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Michael Dambach
Mr. Michael Dambach
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Director
Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jun 25
Updated: Wed, Jun 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Deerfield Management Company, L.P.
9.53%
Cystic Fibrosis Foundation
9.53%
Nantahala Capital Management, LLC
9.53%
Alyeska Investment Group, L.P.
6.08%
AIGH Capital Management, LLC.
4.52%
Other
60.82%
Shareholders
Shareholders
Proportion
Deerfield Management Company, L.P.
9.53%
Cystic Fibrosis Foundation
9.53%
Nantahala Capital Management, LLC
9.53%
Alyeska Investment Group, L.P.
6.08%
AIGH Capital Management, LLC.
4.52%
Other
60.82%
Shareholder Types
Shareholders
Proportion
Hedge Fund
31.66%
Corporation
13.62%
Private Equity
4.52%
Holding Company
4.09%
Investment Advisor
3.77%
Venture Capital
3.72%
Investment Advisor/Hedge Fund
2.37%
Research Firm
1.65%
Individual Investor
1.48%
Other
33.12%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
47
17.51M
66.88%
+4.34M
2025Q1
47
17.95M
68.92%
+5.32M
2024Q4
47
13.90M
76.65%
+2.77M
2024Q3
43
13.00M
74.85%
+8.58M
2024Q2
33
4.45M
66.70%
+1.05M
2024Q1
34
2.97M
56.90%
+586.97K
2023Q4
35
2.25M
51.72%
+502.58K
2023Q3
39
1.91M
46.61%
-56.19K
2023Q2
39
1.94M
47.21%
+273.60K
2023Q1
38
1.06M
33.47%
-530.41K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Deerfield Management Company, L.P.
2.49M
9.53%
+1.25M
+100.00%
Mar 31, 2025
Cystic Fibrosis Foundation
2.49M
9.53%
+706.35K
+39.51%
Feb 27, 2025
Nantahala Capital Management, LLC
2.49M
9.53%
+762.71K
+44.07%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.59M
6.08%
+725.34K
+83.82%
Mar 31, 2025
AIGH Capital Management, LLC.
1.18M
4.52%
+533.12K
+82.04%
Mar 31, 2025
Centaurus Investments Limited
1.07M
4.09%
+1.07M
--
Apr 21, 2025
Allostery Investments LP
940.63K
3.59%
+296.80K
+46.10%
Mar 31, 2025
Ikarian Capital LLC
892.98K
3.41%
--
--
Mar 31, 2025
AMR Action Fund LP
876.89K
3.35%
+571.40K
+187.05%
Sep 30, 2024
Telmina Ltd
560.27K
2.14%
+276.30K
+97.30%
Sep 30, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Date
Type
Ratio
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
